本文選題：二肽基肽酶-抑制劑　切入點：大皰性類天皰瘡　出處：《中國新藥雜志》2017年18期

【摘要】：目的:分析二肽基肽酶-4抑制劑致大皰性類天皰瘡的發(fā)生規(guī)律及特點,為安全用藥提供參考。方法:檢索中國學(xué)術(shù)期刊全文數(shù)據(jù)庫、維普中文科技期刊數(shù)據(jù)庫、萬方數(shù)據(jù)庫和Pubmed數(shù)據(jù)庫收載的二肽基肽酶-4抑制劑致大皰性類天皰瘡文獻并進行分析。結(jié)果:21例不良反應(yīng)中,男性11例,女性10例,年齡60歲及以上患者20例(95.2%)。21例患者中,服用維格列汀者15例,服用西格列汀者3例,服用利拉列汀者3例。用藥至發(fā)生大皰性類天皰瘡的時間為1~37個月,平均時間8個月。結(jié)論:臨床醫(yī)師應(yīng)了解二肽基肽酶-4抑制劑致大皰性類天皰瘡的規(guī)律和特點,加強用藥監(jiān)測,以便及時發(fā)現(xiàn)和處理大皰性類天皰瘡。
[Abstract]:Objective: to analyze the occurrence and characteristics of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitor.Methods: the full text database of Chinese academic journals, the database of Chinese science and technology journals, the database of Wanfang and the database of Pubmed were searched and analyzed in the literature of bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitor.Results of 21 cases, 11 cases were male, 10 cases were female, 20 cases were aged 60 years and above, 15 cases were treated with vigllline, 3 cases were treated with siglitatin, and 3 cases were treated with riparutin.The time from medication to bullous pemphigoid was 1 ~ 37 months, with an average time of 8 months.Conclusion: clinicians should understand the regularity and characteristics of bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitor and strengthen drug monitoring in order to detect and treat bullous pemphigoid in time.
【作者單位】： 安徽省蚌埠市第三人民醫(yī)院藥學(xué)部;
【分類號】：R977.15

【相似文獻】

相關(guān)期刊論文 前2條

1 劉志剛;四環(huán)素和煙酰胺治療大皰性類天皰瘡[J];國外藥學(xué)(抗生素分冊);1987年05期

2 周云龍;;甲滅酸誘發(fā)的大皰性類天皰瘡[J];國外醫(yī)學(xué).皮膚病學(xué)分冊;1987年05期

，

本文編號：1713669